Anzeige
Mehr »
Login
Sonntag, 06.10.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Achtung Vervielfachung! URAN-AKTIEN starten durch …. Jetzt kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PZ7S | ISIN: FR0013481835 | Ticker-Symbol: 7V91
Frankfurt
04.10.24
09:26 Uhr
0,204 Euro
-0,006
-2,63 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
KLEA HOLDING Chart 1 Jahr
5-Tage-Chart
KLEA HOLDING 5-Tage-Chart
RealtimeGeldBriefZeit
0,2080,23805.10.
Actusnews Wire
161 Leser
Artikel bewerten:
(1)

KLEA HOLDING: The offer received by Klea Holding for all its outstanding shares at 0.30 euro per share is extended to October 25th 2024

  • After further discussions between the consortium and Klea Holding's management, the offeror has agreed to extend the offer to Friday 25 October 2024 at 17:00 CET.
  • This extension will allow Klea Holding to have a company valuation made by an independent analyst and to examine the offer in more detail.

Paris, September 27, 2024

KLEA HOLDING (FR0013481835 - ALKLH), a group focused on the acquisition, development, and digitalization of companies across multiple sectors, announces that the proposal from a consortium to make an offer for all outstanding shares of the company at a price of 0.30 euro per share (cf. press release from September 24, 2024) has been extended to October 25th 2024.

Latest developments

The management of Klea Holding has met in Dubai (United Arab Emirates) with the representatives of the consortium of GCC based investors to further review and discuss their offer.

During these discussions, Klea Holding's management has requested an extension to the offer period to be able to examine and analyze the offer in more detail. The consortium agreed to extend their offer to Friday 25 October, 2024 at 17:00 CET.

The Company has mandated an independent financial analyst to carry out a valuation of the company to enable Klea Holding's Board of Directors to form an opinion on the consortium's offer.

The Board of Directors of Klea Holding has approved the proposed extension and approach taken by the company's management.

Reminder of the Offer details

A consortium of GCC based investors has offered to acquire all the issued ordinary shares of Klea Holding. The price set by the consortium is an all-cash tender offer of € 0.30 per Company ordinary share, representing a premium of 58% over the last quoted price before the announcement.

The Board of Directors of Klea Holding has taken note of this proposal and is currently reviewing it, including its conditions precedent and financing. The Board of Directors notes that the offer price of € 0.30 per share consequently values Klea Holding's issued ordinary shares at circa € 92.3 million.

This tender offer will be a voluntary offer under the normal procedure as, to the best of the company's knowledge, the consortium does not own any shares of Klea Holding as of the date of the offer. The consortium intends to implement a minority squeeze-out if it reaches the 90.0% ownership threshold via the tender offer process.

The offer is non-binding and will now end on Friday 25 October 2024 at 17:00 CET.

Next steps

Klea Holding management is in ongoing discussion with the consortium to evaluate the offer in further details.

An independent financial analyst will conduct a valuation of Klea Holding and produce a report which will be submitted to Klea Holding's Board of Directors before the deadline of October 25th 2024.

There is no certainty that these discussions will result in an agreement or transaction, nor as to the conditions and timetable of it.

The offer is subject to the usual conditions precedent, such as the completion of due diligence, the approval of its terms by the Board of Directors and the signature of an agreement with the Company and the main shareholders, as well as a waiver threshold which has been set at 60%.

Klea Holding is committed to keeping the public informed of any significant developments on this matter.

About Klea Holding

Klea Holding is a group focused on acquiring, developing and digitizing companies in various sectors to maximize their growth and value. Through its "scaling industries of the future" identity, Klea Holding draws on its successful experience in developing Smart Salem, the first network of digitalized medical analysis centers accredited by the Dubai Ministry of Health (DHA) in the United Arab Emirates, and its Smart Health joint venture developed in Saudi Arabia, to extend this entrepreneurial approach to the four corners of the globe.

Klea Holding is headquartered in Paris and listed on Euronext Growth (ALKLH). For further information, please visit http://www.kleaholding.com.

Investor Relation: Jérôme FABREGUETTES LEIB // +33 1 53 67 36 78 // kleaholding@actus.fr

Press Relation: Fatou-Kiné N'DIAYE // +33 1 53 67 36 34 // fndiaye@actus.fr

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: ypybZcqbYWeYxmyaZpeWZ2GYmW9qm5HIbGiel2Ztl5rJmJ2UxZhimMeaZnFonmhv
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-87939-alklh-cp-offer-suite-eng.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2024 Actusnews Wire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.